Evidence map›Paper›PMID 23408844›Full record

ArticleMutagenesis2013

Genetic damage in patients with chronic kidney disease, peritoneal dialysis and haemodialysis: a comparative study.

Angélica Rangel-López, Maria Eugenia Paniagua-Medina, Marcia Urbán-Reyes, Martha Cortes-Arredondo, Cleto Alvarez-Aguilar, Joel López-Meza, Alejandra Ochoa-Zarzosa, Bengt Lindholm, Elvia García-López, José Ramón Paniagua

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Mutagenesis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 50 citations in OpenAlex.

  1. Prooxidant effect of uric acid on human leukocytic DNA: An in vitro and ex vivo study.Turkish journal of biology = Turk biyoloji dergisi · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Oxidative Stress in Non-Dialysis-Dependent Chronic Kidney Disease Patients.International journal of environmental research and public health · 2021
    Article
  9. New-Onset Diabetes Mellitus in Peritoneal Dialysis and Hemodialysis Patients: Frequency, Risk Factors, and Prognosis-A Review.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2019
    Review
  10. Review
  11. Review
  12. Article
  13. DNA Damage in Chronic Kidney Disease: Evaluation of Clinical Biomarkers.Oxidative medicine and cellular longevity · 2016
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Angélica Rangel-LópezMedical Research Unit on Nephrological Diseases, Specialties Hospital, National Medical Centre, Century XXI, Mexican Institute for Social Security (IMSS), Mexico City, Mexico. ragn62@prodigy.net.mx
Maria Eugenia Paniagua-Medina
Marcia Urbán-Reyes
Martha Cortes-Arredondo
Cleto Alvarez-Aguilar
Joel López-Meza
Alejandra Ochoa-Zarzosa
Bengt Lindholm
Elvia García-López
José Ramón Paniagua
Mexican Social Security Institute · MXKarolinska Institutet · SEUniversidad Michoacana de San Nicolás de Hidalgo · MXHospital Infantil de México Federico Gómez · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with chronic kidney disease (CKD) have signs of genomic instability and, as a consequence, extensive genetic damage, possibly due to accumulation of uraemic toxins, oxidative stress mediators and other endogenous substances with genotoxic properties. We explored factors associated with the presence and background levels of genetic damage in CKD. A cross-sectional study was performed in 91 CKD patients including pre-dialysis (CKD patients; n = 23) and patients undergoing peritoneal dialysis (PD; n = 33) or haemodialysis (HD; n = 35) and with 61 healthy subjects, divided into two subgroups with the older group being in the age range of the patients, serving as controls. Alkaline comet assay and cytokinesis-block micronucleus assay in peripheral blood lymphocytes were used to determine DNA and chromosome damage, respectively, present in CKD. Markers of oxidative stress [malondialdehyde (MDA), advanced glycation end products (AGEs), thiols, advanced oxidation protein products and 8-hydroxy-2'-deoxyguanosine] and markers of inflammation (C-reactive protein, interleukin-6 and tumour necrosis factor alpha) were also measured. Micronucleus (MN) frequency was significantly higher (P < 0.05) in the CKD group (46±4‰) when compared with the older control (oC) group (27.7±14). A significant increase in MN frequency (P < 0.05) was also seen in PD patients (41.9±14‰) versus the oC group. There was no statistically significant difference for the HD group (29.7±15.6‰; P = NS) versus the oC group. Comet assay data showed a significant increase (P < 0.001) of tail DNA intensity in cells of patients with CKD (15.6±7%) with respect to the total control (TC) group (11±1%). PD patients (14.8±7%) also have a significant increase (P < 0.001) versus the TC group. Again, there was no statistically significant difference for the HD group (12.5±3%) compared with the TC group. Patients with MN values in the upper quartile had increased cholesterol, triglycerides, AGEs and MDA levels and lower albumin levels. Multiple logistic regression analysis showed that male gender, diabetes and treatment modality were independently associated with higher levels of DNA damage. Our results suggest that oxidative stress, diabetes, gender and dialysis modality in CKD patients increased DNA and chromosome damage. To confirm these data, prospective clinical trials need to be performed.

Indexed as

Chromosomal Instability8-Hydroxy-2'-DeoxyguanosineAdultAgedBiomarkersComet AssayC-Reactive ProteinCross-Sectional StudiesDeoxyguanosineDNA DamageFemaleGlycation End Products, AdvancedHumansInflammationInterleukin-6Logistic Models8-Hydroxy-2'-DeoxyguanosineBiomarkersC-Reactive ProteinDeoxyguanosineGlycation End Products, AdvancedInterleukin-6MalondialdehydeSerum AlbuminTriglyceridesTumor Necrosis Factor-alpha

Identifiers

PMID23408844
PMCPMC3570793
OpenAlexW2155729476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.